http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4128288-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8dbdfc93841b3d731fbab7ea48b412a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-34 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-34 |
| filingDate | 1991-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d281c04947029f817b69e7a8f2a8f91e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acd2f147aa8bfabac4c37022d1e6b83c |
| publicationDate | 1993-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-4128288-A1 |
| titleOfInvention | USE OF PAF ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CHOLESTASE AND OTHER DISEASES MARKED BY AN INCREASED LIPOPROTEIN-X MIRROR |
| abstract | The following are claimed: (A) use of PAF-antagonists for (i) treatment or prophylaxis of diseases associated with an elevated level of lipoprotein X in blood, (ii) treatment of cholestasis and lecithin-cholesterol -acyl-transferase (LCAT) deficiency, and (iii) differential diagnosis between cholestatic and non-cholestatic liver disorders. (B) Determination of PAF-acetylthydrolase activity in serum is used for (i) diagnosis of cholestases and LCAT deficiency disorders, (ii) monitoring the course of a cholestatic disease, and (iii) assessing the success of therapy of cholestatic diseases with PAF-antagonists. (C) Use of PAF antagonists in prepn. of medicaments for (i) treatment of prophylaxis of diseases associated with elevated lipoprotein-X levels in blood, and (ii) treatment of cholestasis or LCAT deficiency disease. USE/ADVANTAGE - Presence of lipoprotein X is specific for existence of an intra- or extra-hepatic cholestasis or LCAT-deficiency disease. In these cases the level of PAF-acetyl-hydrolase is also increased. By using a PAF-antagonists to block PAF-receptors the activity of lipoprotein X (which acts at those receptors) is stopped, the elevated level of the lipoprotein X is removed and the disease may be treated. Admin. is topical, oral, parenteral, transdermal or by inhalation in doses of 1-50 (esp. 3-20) mg/dose (p.o.) or 0.01-50 (esp.0.1-10) mg/dose (i.v. or i.m.) |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9717434-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9717434-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6635614-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2670619-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2670619-C9 |
| priorityDate | 1991-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 112.